Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

被引：1
|
作者：
Yamaguchi, Teppei [1 ]
Hida, Toyoaki [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
关键词：
PHASE-III; MAINTENANCE BEVACIZUMAB; CHEMOTHERAPY; COMBINATION; NIVOLUMAB; DOCETAXEL; EFFICACY; THERAPY; SAFETY;
D O I：
10.21037/tcr.2019.12.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 50 条
  • [31] Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Hawkins, M. J.
    Manikhas, G.
    Makhson, A.
    Cheporov, S.
    Orlov, S.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PERIPHERAL NEUROPATHY
    Sakai, Hiroshi
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S569 - S570
  • [33] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): AN ECONOMIC ANALYSIS
    Spigel, David
    Harwin, William
    Dranitsaris, George
    Binder, Gary
    Weber, Paul
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1176 - S1177
  • [34] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer NSCLC: Dose Modification Analysis
    Postmus, Pieter E.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Li, Li
    Ong, Teng Jin
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S658 - S658
  • [35] Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    West, Howard
    McCleod, Michael
    Hussein, Maen
    Morabito, Alessandro
    Rittmeyer, Achim
    Conter, Henry J.
    Kopp, Hans-Georg
    Daniel, Davey
    McCune, Steven
    Mekhail, Tarek
    Zer, Alona
    Reinmuth, Niels
    Sadiq, Ahad
    Sandler, Alan
    Lin, Wei
    Lohmann, Tania Ochi
    Archer, Venice
    Wang, Lijia
    Kowanetz, Marcin
    Cappuzzo, Federico
    LANCET ONCOLOGY, 2019, 20 (07): : 924 - 937
  • [36] The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease
    Fujita, Tetsuo
    Hiroishi, Takuma
    Yanagisawa, Asako
    Hayama, Noriko
    Amano, Hiroyuki
    Nakamura, Makoto
    Hirano, Satoshi
    Tabeta, Hiroshi
    Nakamura, Sukeyuki
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [37] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
  • [38] nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study
    Spigel, D. R.
    Jotte, R. M.
    Ponce Aix, S.
    Gressot, L.
    Morgensztern, D.
    McCleod, M.
    Socinski, M. A.
    Daniel, D.
    Juan-Vidal, O.
    Kim, E. S.
    West, H. J.
    Chen, T.
    Bhore, R.
    Ong, T. J.
    Gridelli, C.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
    Tabah, Ashley
    Huggar, David
    Kish, Jonathan
    Bapat, Bela
    Liassou, Djibril
    Gajra, Ajeet
    Miller, Talia
    Copher, Ronda
    Patel, Manali, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Owen, S. P.
    Ko, A.
    Renschler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S21 - S21
12345